Population‐Based Pharmacokinetic and Exposure‐Efficacy Analyses of Peginterferon Beta‐1a in Patients With Relapsing Multiple Sclerosis

Peginterferon beta‐1a reduced annualized relapse rate as compared with placebo and was approved to treat multiple sclerosis patients. A population pharmacokinetic and an exposure‐efficacy model were developed to establish the quantitative relationship between pharmacokinetics and annualized relapse...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Xiao, Hang, Yaming, Cui, Yue, Zhang, Jie, Liu, Shifang, Seddighzadeh, Ali, Deykin, Aaron, Nestorov, Ivan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Pharmacometrics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5516189/
https://www.ncbi.nlm.nih.gov/pubmed/28394418
http://dx.doi.org/10.1002/jcph.883

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5516189/
https://www.ncbi.nlm.nih.gov/pubmed/28394418
http://dx.doi.org/10.1002/jcph.883

Ejemplares similares